Updated efficacy and safety of lenvatinib (LEN) plus pembrolizumab (pembro) vs treatment of physician's choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Study 309/KEYNOTE-775

V Makker; N Colombo; A Casado Herraez; B. J Monk; H Mackay; A. D Santin; D. S Miller

doi:10.1016/j.annonc.2022.07.653

Back

Updated efficacy and safety of lenvatinib (LEN) plus pembrolizumab (pembro) vs treatment of physician's choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Study 309/KEYNOTE-775

Conference proceeding

Open access

Peer reviewed

Updated efficacy and safety of lenvatinib (LEN) plus pembrolizumab (pembro) vs treatment of physician's choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Study 309/KEYNOTE-775

V Makker, N Colombo, A Casado Herraez, B. J Monk, H Mackay, A. D Santin and D. S Miller

2022

DOI: https://doi.org/10.1016/j.annonc.2022.07.653

Abstract

Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) -- SEP 09-13, 2022 -- ELECTR NETWORK Eisai Inc., Nutley, NJ, USA; Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA Eisai Inc., Nutley, NJ, USA, and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Files and links (1)

url

https://doi.org/10.1016/j.annonc.2022.07.653View

Published (Version of record) Open

Metrics

1 Record Views

Details

Title: Updated efficacy and safety of lenvatinib (LEN) plus pembrolizumab (pembro) vs treatment of physician's choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Study 309/KEYNOTE-775
Creators: V Makker
N Colombo
A Casado Herraez
B. J Monk
H Mackay
A. D Santin
D. S Miller
Publisher: Elsevier
Identifiers: 991005969138502656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Conference proceeding